SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-22-011393
Filing Date
2022-11-14
Accepted
2022-11-14 16:27:32
Documents
13
Period of Report
2022-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K admp-8k_111422.htm   iXBRL 8-K 23995
2 PRESS RELEASE ISSUED NOVEMBER 14, 2022 ex99-1.htm EX-99.1 37720
  Complete submission text file 0001387131-22-011393.txt   243436

Data Files

Seq Description Document Type Size
3 XBRL LABEL FILE admp-20221114_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE admp-20221114_pre.xml EX-101.PRE 22385
5 XBRL SCHEMA FILE admp-20221114.xsd EX-101.SCH 3266
7 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_111422_htm.xml XML 3589
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 221386227
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences